This ophthalmic preparation is indicated for lowering intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension who do not achieve adequate control with single-agent therapy.

Bimatoprost reduces intraocular pressure by increasing the outflow of aqueous humor through both trabecular meshwork and uveoscleral pathways. It mimics the action of naturally occurring prostaglandins, enhancing drainage of fluid from the eye. It may also reduce aqueous humor production, contributing further to pressure reduction.

Timolol is a non-selective beta-adrenergic receptor blocker that lowers intraocular pressure by decreasing the production of aqueous humor in the eye. It does not exhibit significant intrinsic sympathomimetic, myocardial depressant, or membrane-stabilizing activity. When applied topically, it effectively reduces both elevated and normal intraocular pressure, thereby helping to prevent optic nerve damage and visual field loss associated with glaucoma.

The advised dose is one drop in the affected eye(s) once daily.

Pediatric Use: The safety and efficacy in pediatric patients have not been established.

Geriatric Use: No significant differences in safety or effectiveness have been observed between elderly and other adult patients.

There is a risk of bradycardia when ophthalmic beta-blockers are used together with oral calcium channel blockers, guanethidine, other beta-blockers, parasympathomimetic agents, antiarrhythmic drugs, or digitalis glycosides. Other eye medications should be administered at least 5 minutes apart from this eye drop.

This medication is contraindicated in patients with known hypersensitivity to any of its components.

In clinical studies, ocular hyperemia was reported in about 26% of patients. Other adverse effects observed in 5–10% of patients included reduced vision, eye discomfort, foreign body sensation, pain, and itching.

Pregnancy: There are insufficient data regarding the use of the Bimatoprost/Timolol combination in pregnant women. It should be used during pregnancy only if clearly necessary.

Lactation: Bimatoprost has been found to be excreted in animal milk, and Timolol is excreted in human milk. Therefore, this combination should not be used during breastfeeding.

Topically applied ophthalmic products like Timolol/Bimatoprost may be systemically absorbed. Due to the beta-adrenergic blocking effect of Timolol, adverse reactions similar to systemic beta-blockers, including cardiovascular and pulmonary effects, may occur. Caution is advised in patients with severe, unstable, or uncontrolled cardiovascular disease.

Other ophthalmic preparations

Store below 25°C in a dry place, protected from light. Keep out of reach of children. The solution should be used within 28 days after first opening.